Lars Klareskog

Rheumatology · 2003–2023

A researcher in the Science corpus: 4 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom Lars Klareskog trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. M. Feldmann

Papers from Lars Klareskog's perspective

Ordered by how strongly the researchers Lars Klareskog trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. (New England Journal of Medicine)
  2. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. (The Lancet)
  3. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? (Annual Review of Immunology)
  4. The British Society for Rheumatology Biologics Register (Annals of the Rheumatic Diseases)
  5. NF-κB functions as a tumour promoter in inflammation-associated cancer (Nature)
  6. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. (Arthritis & Rheumatism)
  7. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. (Gastroenterology)
  8. Cytokine pathways and joint inflammation in rheumatoid arthritis. (New England Journal of Medicine)
  9. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. (Gastroenterology)
  10. Development of anti-TNF therapy for rheumatoid arthritis (Nature reviews. Immunology)

Their papers